186 related articles for article (PubMed ID: 34626221)
21. Genomics of uterine leiomyomas: insights from high-throughput sequencing.
Mehine M; Mäkinen N; Heinonen HR; Aaltonen LA; Vahteristo P
Fertil Steril; 2014 Sep; 102(3):621-9. PubMed ID: 25106763
[TBL] [Abstract][Full Text] [Related]
22. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
23. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
24. Gene fusions characterize a subset of uterine cellular leiomyomas.
Hodgson A; Swanson D; Tang S; Dickson BC; Turashvili G
Genes Chromosomes Cancer; 2020 Jul; ():. PubMed ID: 32677742
[TBL] [Abstract][Full Text] [Related]
25. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors.
Markowski DN; Huhle S; Nimzyk R; Stenman G; Löning T; Bullerdiek J
Genes Chromosomes Cancer; 2013 Mar; 52(3):297-304. PubMed ID: 23225304
[TBL] [Abstract][Full Text] [Related]
26. Hydropic leiomyoma: a distinct variant of leiomyoma closely related to HMGA2 overexpression.
Griffin BB; Ban Y; Lu X; Wei JJ
Hum Pathol; 2019 Feb; 84():164-172. PubMed ID: 30292626
[TBL] [Abstract][Full Text] [Related]
27. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
28. MED12 exon 2 mutation is uncommon in intravenous leiomyomatosis: clinicopathologic features and molecular study.
Wang L; Hu S; Xin F; Zhao H; Li G; Ran W; Xing X; Wang J
Hum Pathol; 2020 May; 99():36-42. PubMed ID: 32240666
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma.
Zhu XQ; Shi YF; Cheng XD; Zhao CL; Wu YZ
Gynecol Oncol; 2004 Jan; 92(1):71-9. PubMed ID: 14751141
[TBL] [Abstract][Full Text] [Related]
30. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
31. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
32. Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.
Wu X; Serna VA; Thomas J; Qiang W; Blumenfeld ML; Kurita T
Cancer Res; 2017 Dec; 77(24):6891-6901. PubMed ID: 29055020
[TBL] [Abstract][Full Text] [Related]
33. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
[TBL] [Abstract][Full Text] [Related]
34. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
35. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
36. Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy.
Äyräväinen A; Pasanen A; Ahvenainen T; Heikkinen T; Pakarinen P; Härkki P; Vahteristo P
Hum Reprod; 2020 Oct; 35(10):2237-2244. PubMed ID: 32829387
[TBL] [Abstract][Full Text] [Related]
37. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody.
Sumathi VP; Al-Hussaini M; Connolly LE; Fullerton L; McCluggage WG
Int J Gynecol Pathol; 2004 Jul; 23(3):241-7. PubMed ID: 15213600
[TBL] [Abstract][Full Text] [Related]
38. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
39. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
40. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma.
Rush DS; Tan J; Baergen RN; Soslow RA
Am J Surg Pathol; 2001 Feb; 25(2):253-8. PubMed ID: 11176075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
